3

FORM 3 SUBMISSION

Company: Viridian Therapeutics, Inc.\DE
Filed: February 13, 2017
Period of Report: February 13, 2017
Accession Number: 0001209191-17-010095

View Document ↗ View on SEC.gov ↗